RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 14 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 14

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  2. Study siteDongguan People's Hospital东莞市人民医院DongguanHospital page
  3. Study siteFirst Affiliated Hospital of Gannan Medical University赣南医科大学第一附属医院GanzhouHospital page
  4. Study siteFirst Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院GuangzhouHospital page
  5. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  6. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  7. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  8. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  9. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  10. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  11. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  12. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  13. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  14. Study siteZhongshan City People's Hospital中山市人民医院ZhongshanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06839066, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed recurrent/metastatic nasopharyngeal carcinoma;

    Inclusion criterion 3

  3. History of other malignancies within 2 years prior to randomization (except radically treated early-stage malignancies).

    Exclusion criterion 3

  4. Recurrent/metastatic nasopharyngeal carcinoma patients who have failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen) and PD-1/PD-L1 inhibitor therapy. Intolerance is defined as experiencing CTCAE ≥ grade 3 adverse events;

    Inclusion criterion 4

    At least 4 weeks (or 5 half-lives, whichever is shorter) since last major surgery, medical device treatment, radiotherapy (except palliative bone radiotherapy), cytotoxic chemotherapy, immunotherapy, or biological therapy; ≥2 weeks since last hormonal therapy or small molecule targeted therapy; ≥1 week since last traditional Chinese medicine treatment with anti-tumor indications or minor surgery; with treatment-related adverse events recovered to CTCAE v5.0 ≤ grade 1 (except grade 2 peripheral neuropathy and alopecia);

    Inclusion criterion 7

    Previous ≥Grade 3 immune-related adverse events during immunotherapy.

    Exclusion criterion 4

  5. ECOG performance status 0-1 within 1 week before randomization;

    Inclusion criterion 8

  6. At least one measurable lesion per RECIST v1.1 within 4 weeks before randomization;

    Inclusion criterion 5

  7. Immunodeficiency disorders (HIV-positive or congenital/acquired immune deficiencies).

    Exclusion criterion 17

    Active HBV/HCV infection or co-infection:

    Exclusion criterion 18

  8. Fertile participants must use ≥1 highly effective contraceptive method during the trial and for ≥6 months after last dose; females of childbearing potential must have negative pregnancy test within 7 days before enrollment.

    Inclusion criterion 11

    Pregnant/lactating women.

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06839066, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fully understand the study content, procedures, and potential adverse reactions before the trial, sign the informed consent form (ICF), voluntarily participate in the trial, and be able to complete the study per the protocol requirements;
  • Age ≥ 18 years at the time of signing the ICF, regardless of gender;
  • Histologically or cytologically confirmed recurrent/metastatic nasopharyngeal carcinoma;
  • Recurrent/metastatic nasopharyngeal carcinoma patients who have failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen) and PD-1/PD-L1 inhibitor therapy. Intolerance is defined as experiencing CTCAE ≥ grade 3 adverse events;
  • At least one measurable lesion per RECIST v1.1 within 4 weeks before randomization;
  • Willing to provide archived (preferably within 2 years) or fresh tumor tissue specimens for the detection of PD-L1 expression.
  • At least 4 weeks (or 5 half-lives, whichever is shorter) since last major surgery, medical device treatment, radiotherapy (except palliative bone radiotherapy), cytotoxic chemotherapy, immunotherapy, or biological therapy; ≥2 weeks since last hormonal therapy or small molecule targeted therapy; ≥1 week since last traditional Chinese medicine treatment with anti-tumor indications or minor surgery; with treatment-related adverse events recovered to CTCAE v5.0 ≤ grade 1 (except grade 2 peripheral neuropathy and alopecia);
  • ECOG performance status 0-1 within 1 week before randomization;
  • Expected survival ≥ 3 months;
  • Adequate organ function within 1 week before randomization (no blood transfusion or colony-stimulating factors within 14 days prior to first dose)
  • Fertile participants must use ≥1 highly effective contraceptive method during the trial and for ≥6 months after last dose; females of childbearing potential must have negative pregnancy test within 7 days before enrollment.

Exclusion Criteria:

  • Recurrent nasopharyngeal carcinoma candidates eligible for curative local therapy (surgery or radiotherapy).
  • Imaging showing tumor invasion/encasement of major thoracic/cervical/pharyngeal blood vessels (may be exempted if investigators confirm no impact on trial participation).
  • History of other malignancies within 2 years prior to randomization (except radically treated early-stage malignancies).
  • Previous ≥Grade 3 immune-related adverse events during immunotherapy.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • Symptomatic/untreated/progressing CNS or leptomeningeal metastases.
  • History of ≥Grade 3 radiation pneumonitis; steroid-requiring (non-infectious) interstitial lung disease (ILD), current ILD, or ILD unexcludable by imaging; or severe respiratory impairment from pulmonary disease.
  • Poorly controlled cardiovascular/cerebrovascular conditions including.
  • Candidates for organ/marrow transplantation or previous transplant recipients.
  • Active systemic infections requiring IV antibiotics within 2 weeks pre-randomization.
  • Use of strong CYP2D6/CYP3A inhibitors/inducers within 2 weeks pre-randomization.
  • Systemic corticosteroid use (>10mg prednisone/day equivalent) or immunosuppressants within 2 weeks pre-randomization. Exceptions: Topical/ocular/intra-articular/nasal/inhaled steroids; short-term prophylactic use for contrast agents.
  • Active/suspected autoimmune diseases. Exceptions: Hypothyroid patients on thyroid replacement; controlled type 1 diabetes with insulin.
  • Live/attenuated vaccines within 4 weeks pre-randomization (inactivated influenza vaccines permitted).
  • History of severe hypersensitivity to biologics/monoclonal antibodies or trial drug components.
  • Active tuberculosis.
  • Immunodeficiency disorders (HIV-positive or congenital/acquired immune deficiencies).
  • Active HBV/HCV infection or co-infection:
  • Pregnant/lactating women.
  • Investigators' judgment of clinical/lab abnormalities or other factors making participation inappropriate.

Quoted from ClinicalTrials.gov, NCT06839066, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06839066, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06839066